

<b>Day 1</b>	<b>Public Health and Epidemiology</b>		
<b>07:00</b>	<b>Registration</b>		
	<b>Level 8</b>		
<b>08:30 - 09:00</b>	<b>Opening Ceremony</b> Room: Montreal Ballroom, Level 11 Chairs: Julie Bruneau, Marina Klein, and Jason Grebely		
<b>08:30 - 08:45</b>	<b>Welcome to the Conference</b>		
<b>08:45 - 08:50</b>	<b>Community Opening</b>		
<b>08:50 - 09:00</b>	<b>Awards</b>		
<b>09:00 - 10:45</b>	<b>Session A: Public Health and Epidemiology</b> Room: Montreal Ballroom, Level 11 Chairs: Margaret Hellard and Matthew Hickman		
<b>09:00 - 09:20</b>	<b>The changing landscape of drug use globally: Implications for hepatitis C elimination</b> Louisa Degenhardt, UNSW Sydney, Australia		
<b>09:20 - 09:25</b>	<b>Questions &amp; Discussion</b>		
<b>09:25 - 09:45</b>	<b>Global progress towards hepatitis C elimination: success and challenges</b> Margaret Hellard, Burnet Institute, Australia		
<b>09:45 - 10:00</b>	<b>The Scottish Experience: Reduction in the Population Prevalence of Chronic HCV among People Who Inject Drugs Associated with Major Scale-Up of Direct-Acting Antiviral Therapy in Community Drug Services: Real World Data</b> Norah Palmateer, Glasgow Caledonian University, Glasgow		
<b>10:00 - 10:10</b>	<b>The Georgian experience. Not just cure. The broader benefits of providing hepatitis C treatment in needle and syringe programs services</b> Maia Butashvili, Health Research Union, Georgia		
<b>10:10 - 10:20</b>	<b>The Iceland experience. Getting the band together: The importance of bringing together government, hepatology, infectious diseases, drug and alcohol services and the prison sector to engage with people who inject drugs in hepatitis C care</b> Sigurdur Olafsson, Landspítali University Hospital, Iceland		
<b>10:20 - 10:30</b>	<b>Questions &amp; Discussion</b>		
<b>10:30 - 10:45</b>	<b>Life and loss in the race to elimination: What does viral elimination potentiate and what does it leave behind?</b> Kari Lancaster, Centre For Social Research In Health, UNSW, Australia		
<b>10:45 - 11:15</b>	<b>Coffee Break and Poster Viewing</b>		
	<b>Level 9</b>		
<b>11:15 - 12:15</b>	<b>Session B: Mathematical Modelling to Inform Practice and Policy</b> Room: Montreal Ballroom, Level 11 Chairs: Tim Rhodes and Kari Lancaster		
<b>11:15 - 11:35</b>	<b>How can mathematical modelling be used to better inform research, practice and policy in hepatitis C and drug user health?</b> Peter Vickerman, University of Bristol, United Kingdom		
<b>11:35 - 11:45</b>	<b>Questions &amp; Discussion</b>		
<b>11:45 - 11:55</b>	<b>Case Study 1</b> Natalasha Martin, University of California San Diego, United States		
<b>11:55 - 12:05</b>	<b>Case Study 2</b> Homie Razavi, CDA Foundation, United States		
<b>12:05 - 12:15</b>	<b>Case Study 3</b> John Dillon, University of Dundee, United Kingdom		
<b>12:15 - 14:00</b>	<b>Lunch &amp; Poster Viewing</b>		
	<b>Level 8</b>		
<b>12:45 - 13:45</b>	<b>Industry Sponsored Symposium: Working Together toward HCV Elimination in People Who Use Substances: A Multidisciplinary Approach</b> Room: Fortifications, Level 9		
<b>14:00 - 15:20</b>	<b>Session C: Progress towards hepatitis C elimination</b> Room: Montreal A & B, Level 11 Chairs: Philip Brannon and Adalina Artenie	<b>14:00 - 15:20</b>	<b>Session D: Ways to improve HCV testing, treatment and care</b> Room: Montreal C & D, Level 11 Chairs: Mel Kriston and Lisa Lafferty
<b>14:00 - 14:15</b>	<b>High uptake of direct-acting antiviral therapy for hepatitis C virus and reduction in population-level viremic prevalence: Progress toward achieving hepatitis C elimination among people who inject drugs in Australia</b> Heather Valerio, The Kirby Institute, UNSW Sydney, Australia	<b>14:00 - 14:15</b>	<b>Task shifting in HCV testing and research: improving knowledge of HCV status through a peer outreach hepatitis c point of care project in Toronto, Canada</b> Jennifer Broad, South Riverdale Community Health Centre, Canada
<b>14:15 - 14:30</b>	<b>Recent opioid agonist therapy and hepatitis C virus treatment uptake among people who inject drugs with chronic hepatitis C infection in a population based data linkage study</b> Sofia Bartlett, BC Centre For Disease Control, Canada	<b>14:15 - 14:30</b>	<b>Maximising adherence to direct-acting antivirals among street-based and marginalised clients: The results of daily dosing</b> Phillip Read, Kerketon Road Centre, Australia
<b>14:30 - 14:45</b>	<b>An intervention to improve HCV testing, linkage to care, and treatment among people who use drugs in Tehran, Iran: The ENHANCE study</b> Maryam Alavi, The Kirby Institute, UNSW Sydney, Australia	<b>14:30 - 14:45</b>	<b>Changes in attitudes, knowledge and everyday life throughout direct-acting antiviral treatment for hepatitis c: a longitudinal qualitative study</b> Stelliana Goutzamanis, Burnet Institute, Australia
<b>14:45 - 14:50</b>	<b>The evolving hepatitis C care cascade in a real-world setting: results for the period 2003-2017 from Free Clinic Antwerp</b> Catharina Mathot, Free Clinic Antwerp, Belgium	<b>14:45 - 14:50</b>	<b>Factors that influence people who use drugs' experiences with direct-acting antiviral treatment for hepatitis c: a qualitative study in Vancouver, Canada</b> Rod Knight, National Prisons Hepatitis Network, Australia
<b>14:50 - 14:55</b>	<b>Early impact of direct-acting antivirals on chronic hepatitis C prevalence among people who inject drugs in England: Real world data, 2011-2017</b> Megan Bardsley, Public Health England, United Kingdom	<b>14:50 - 14:55</b>	<b>Dispensing mode and hepatitis c direct acting antiviral treatment completion</b> John Koo, Vancouver Coastal Health, Canada
<b>14:55 - 15:00</b>	<b>Opportunities for engaging patients in care along the hepatitis C cascade of care</b> Alicia Pedrana, Burnet Institute, Australia	<b>14:55 - 15:00</b>	<b>HCV support groups: do they still have a role in the DAA era?</b> Tianna Margel, Vancouver Infectious Diseases Centre, Canada
<b>15:00 - 15:05</b>	<b>A one-stop community-based approach for HCV screening, diagnosis and treatment among people who inject drugs in Iran: The Rostam study</b> Samira Hosseini Hooshyar, The Kirby Institute, UNSW Sydney, Australia	<b>15:00 - 15:05</b>	<b>Peers4wellness: Indigenous model for supportive HCV and HIV care</b> Sadeem Fayed, Simon Fraser University, Canada
<b>15:05 - 15:10</b>	<b>Decreasing hepatitis C incidence and prevalence through enhancing HCV care and treatment among HIV co-infected individuals: The CO-EC study outcomes</b> Joseph Doyle, Burnet Institute, Australia	<b>15:05 - 15:10</b>	<b>A two-eyed seeing approach to wholistic healing and wellness for people with drug use experience</b> Matthew Fischer, Indigenous Wellness Research Group, Canada
<b>15:10 - 15:15</b>	<b>Engaging drug using communities to scale up diagnosis and inform national HIV/HCV elimination efforts</b> Annette Gaudino, Treatment Action Group, United States	<b>15:10 - 15:15</b>	<b>Enhanced self-efficacy for HCV management among people participating an HCV education program focused on drug and alcohol and primary care settings</b> Nikilah Habraken, Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine, Australia
		<b>15:15 - 15:20</b>	<b>Accessible care intervention for engaging people who inject illicit drugs in hepatitis C virus care: preliminary results from a randomized clinical trial</b> Benjamin Eckhardt, New York University School Of Medicine, United States
<b>15:20 - 16:15</b>	<b>Coffee Break &amp; Poster Tour</b>		
	<b>Level 8</b>		
<b>15:30 - 16:00</b>	<b>Poster Tour 1: Social Science</b> Chair: Lisa Lafferty		
<b>15:30 - 15:35</b>	<b>Beyond Clinical Outcomes: Impact and Wider Social and Healthcare System Implications of Hepatitis C Virus (HCV) Treatment and Cure</b> Darcy Bowman, Gilead Sciences, United Kingdom	<b>15:30 - 15:35</b>	<b>Inconsistencies in Methodology, Reporting, and Subjective Description of Hepatitis C Virus Reinfection Rates Among People Who Inject Drugs: Potential Contribution to Stigma and Discrimination?</b> Sofia Bartlett, BC Centre for Disease Control, Canada
<b>15:35 - 15:40</b>	<b>Hepatitis C Treatment: Peer Insights to Understanding Enablers and Impediments to DAA Uptake Among People Who Inject Drugs</b> Susan Chong, La Trobe University, Australia	<b>15:35 - 15:40</b>	
<b>15:40 - 15:45</b>	<b>HCV Crisis Among Russian-Speaking Injecting Drug Users in France: The Urgent Need to Improve Access to Care and Social Integration</b> Marie Jauffret-Roustide, INSERM, France	<b>15:40 - 15:45</b>	<b>Detecting Hepatitis C Virus Transmission Clusters Using Remnant Serum Specimens from Key Affected Populations Tested in Public Health Settings</b> Karl Hochstatter, University Of Wisconsin Madison, United States
<b>15:45 - 15:50</b>	<b>Factors Associated with Low Rates of Engagement in Opioid Substitution Treatment Among People Who Use Drugs in Athens</b> George Kalamitis, Hellenic Liver Patient Association, Greece	<b>15:45 - 15:50</b>	<b>What is the optimal HCV elimination strategy among PWID in a middle-income, high burden setting? A modeling and economic analysis in Tijuana, Mexico</b> Lara Marquez, University of California San Diego, United States
<b>15:50 - 15:55</b>	<b>The Implementation of Harm Reduction and Hepatitis C Services for People Who Inject Drugs in Europe: Results from the 2018 Hep-Core Survey</b> Adam Palayew, McGill University, Canada	<b>15:50 - 15:55</b>	<b>Community-Based Point-of-Care Testing and Treatment for People Who Inject Drugs in Myanmar</b> Bridget Draper, Burnet Institute, Australia
<b>15:55 - 16:00</b>	<b>Cost of Hepatitis C Care Facilitation For HIV/Hepatitis C Co-Infected People Who Use Substances</b> Bruce Schackman, Weill Cornell Medicine, United States	<b>15:55 - 16:00</b>	<b>Willingness to Access Community-Based Hepatitis C and HIV Testing Centres Among Injecting Drug Users in Lagos Nigeria</b> Olanrewaju Onigbogi, University of Eastern Finland, Finland
<b>16:15 - 17:45</b>	<b>Session F: Prevention of Hepatitis C</b> Room: Montreal A & B, Level 11 Chairs: Natasha Martin and Niklas Luhmann		
<b>16:15 - 16:35</b>	<b>Hepatitis C reinfection among people who inject drugs: Should we worry?</b> Harvard Midgard, Oslo University Hospital, Norway	<b>16:15 - 17:45</b>	<b>Session G: Decolonizing hepatitis C treatment and research: Innovative approaches by and with Indigenous people</b> Room: Montreal C & D, Level 11 Chairs: Alexandra King and Renée Masching
		<b>16:15 - 16:35</b>	<b>Territorial Acknowledgement /Welcome to Territory</b>
		<b>16:20 - 16:25</b>	<b>Opening Blessing</b> Elder Sharon Jinkerson Brass, Key First Nation, Canada & Sadeem Fayed, Indigenous Wellness Research Group, Canada
		<b>16:25 - 16:35</b>	<b>Overview</b> Alexandra King, University of Saskatchewan, Canada & Renée Masching, Canadian Aboriginal AIDS Network, Canada
<b>16:35 - 16:55</b>	<b>Opportunities and challenges for harm reduction and HCV prevention among people who use drugs: South African reflections</b> Andrew Schebe, TB HIV Care, South Africa	<b>16:35 - 16:55</b>	<b>Developing new pathways of care in addiction services; a partnership between Onentokon Healing Lodge and the Centre hospitalier de l'Université de Montréal</b> Ariette Ven Den Herde, Onentokon Healing Lodge, Canada & Stéphanie Marsan, Centre hospitalier de l'Université de Montréal, Canada
<b>16:55 - 17:15</b>	<b>What does the future hold for a hepatitis C vaccine?</b> Naglaa Shoukry, Université de Montréal, Canada	<b>16:55 - 17:15</b>	<b>Dried blood spots and disruptive innovation: Empowerment of Indigenous communities to address the colonial etiology of hepatitis C</b> Anne Beck, Kitchenuhmaykoosib Inninuwug (Big Trout) First Nation, Canada & John Kim, National Laboratory for HIV Reference Services, Public Health Agency of Canada, Canada
<b>17:15 - 17:45</b>	<b>Questions &amp; Discussion</b>		
		<b>17:15 - 17:45</b>	<b>Healing through research: Indigenous research methodologies in the substance use and hepatitis C space</b> Elder Sharon Jinkerson Brass, Key First Nation, Canada & Sadeem Fayed, Indigenous Wellness Research Group, Canada
		<b>17:35 - 17:45</b>	<b>Questions &amp; Discussion</b>
<b>17:45 - 19:00</b>	<b>Welcome Reception &amp; Poster Viewing</b>		

<b>Day 2</b>	<b>HCV Diagnosis, Linkage to Care and Treatment</b>						
<b>07.30</b>	<b>Registration</b>						
<b>08.00 - 08.45</b>	<b>Industry Sponsored Symposium: A step closer to achieving HCV elimination in substance users</b> Room: Fortifications, Level 9						
<b>09.00 - 10.45</b>	<b>Session I: Moving from clinical trials to the real-world</b> Room: Montreal Ballroom, Level 11 Chairs: Shruti Mehta and Gregory Dore						
<b>09.00 - 09.20</b>	<b>Overcoming barriers to integrating hepatitis C testing, linkage to care and treatment into existing services: success stories from low and middle income countries</b> Sunil Solomon, Johns Hopkins University, United States						
<b>09.20 - 09.40</b>	<b>Moving from clinical trials to the real world: Effectiveness research for hepatitis C</b> Lisa R. Metsch, Columbia University, United States						
<b>09.40 - 10.00</b>	<b>Skype Presentation: Supporting enhanced efforts to address hepatitis C and health for people who use drugs through strong government leadership</b> Ricardo Baptiste Leite, UNITE, Portugal						
<b>10.00 - 10.15</b>	<b>Questions &amp; Discussion</b>						
<b>10.15 - 10.30</b>	<b>Australia will need to increase testing to achieve hepatitis C elimination</b> Nick Scott, Burnet Institute, Australia						
<b>10.30 - 10.45</b>	<b>Barriers and facilitators to engaging in HCV management and DAA therapy among general practitioners and drug and alcohol specialists - The practitioner experience</b> Alison Marshall, The Kirby Institute, UNSW Sydney, Australia						
<b>10.45 - 11.15</b>	<b>Coffee Break &amp; Poster Viewing</b> Level 8						
<b>11.15 - 12.15</b>	<b>Session K: Hepatitis C risk and prevention</b> Room: Montreal A & B, Level 11 Chairs: Hannah Fraser and Behzad Hajarizadeh	<b>11.15 - 12.15</b>	<b>Session L: Enhancing hepatitis C testing and linkage to care</b> Room: Montreal C & D, Level 11 Chairs: Valerie Martel-Laferriere and Joshua Barocas	<b>11.15 - 12.15</b>	<b>Session J Workshop 1: Peers facilitating access to their criminalized communities improving the hep c cascade of care: How to meaningfully engage and involve people with lived experience (PWLE) in your programs</b> Room: Fortifications, Level 9 Chairs: Jennifer Broad & Jude Byrne	<b>11.15 - 12.15</b>	<b>Session J Workshop 2: From the Frontline: A networking session</b> Room: Ville-Marie, Level 9 Chairs: John Dillon
<b>11.15 - 11.30</b>	<b>Association between short-term housing patterns and hepatitis C acquisition: findings from a cohort of people who inject drugs in Montréal, Canada</b> Emmanuel Fortier, CHUM Research Centre, Canada	<b>11.15 - 11.30</b>	<b>Making Oraquick quicker: A hepatitis C point-of-care test reduced to five minutes for viremic individuals</b> Aaron Vanderhoff, Viral Hepatitis Care Network, Canada	<i>This session will provide an opportunity to meet, network and collaborate with other service providers, program planners, community members and researchers who have a focus on front-line services and programs. You'll engage in facilitated discussions on approaches in four settings: prisons, harm reduction and needle-syringe programs, addiction medicine and opioid substitution therapy, and mobile and community-based.</i>  <i>This session is presented by INHSU and CATIE. CATIE is Canada's source for HIV and hepatitis C information</i>			
<b>11.30 - 11.45</b>	<b>Diversity of detention patterns among people who inject drugs and the associated risk with incident hepatitis C virus (HCV) infection: Implications for HCV prevention</b> Andreea Adelina Arteni, University Of Montréal, Canada	<b>11.30 - 11.45</b>	<b>Time to detection of hepatitis C virus infection with the Xpert HCV Viral Load finger-stick point-of-care assay: Facilitating a more rapid time to diagnosis</b> Jason Grebely, The Kirby Institute, UNSW Sydney, Australia				
<b>11.45 - 12.00</b>	<b>Modelling the impact of prevention and treatment interventions for people who inject drugs in Dar es Salaam, Tanzania</b> Hannah Fraser, University of Bristol, United Kingdom	<b>11.45 - 12.00</b>	<b>Targeted testing pathways improve hepatitis C diagnosis rates</b> Emma Robinson, University Of Dundee, United Kingdom				
<b>12.00 - 12.05</b>	<b>HIV and HCV among people who inject drugs in Ukraine: a stabilization or a calm before the storm?</b> Marina Kornilova, Alliance For Public Health, Ukraine	<b>12.00 - 12.05</b>	<b>Cost-effectiveness of hepatitis C virus screening and treatment with direct-acting antivirals in people who inject drugs in Nairobi, Kenya</b> Jack Stone, University Of Bristol, United Kingdom				
<b>12.05 - 12.10</b>	<b>HCV among people who inject drugs in France: Acting on risk environment in an evolving crisis</b> Marie Jauffret-Roustide, Inserm, France	<b>12.05 - 12.10</b>	<b>The cost-effectiveness of an HCV outreach intervention for at-risk populations in London, UK</b> Zoe Ward, University Of Bristol, United Kingdom				
<b>12.10 - 12.15</b>	<b>The Brazilian syndemics of crack use, HIV and HCV</b> Alexandra Almeida, SDSU, United States	<b>12.10 - 12.15</b>	<b>Using a systems-thinking approach to elucidate programme theory underpinning the effectiveness of Superdot-C: a pharmacy-led test and treat pathway for PWIDS with</b> Andrew Radley, NHS Tayside, United Kingdom				
<b>12.15 - 14.00</b>	<b>Lunch and Poster Viewing</b> Level 8						
<b>12.45 - 13.45</b>	<b>Industry Sponsored Symposium: Transforming HCV care: the power of collaboration</b> Room: Fortifications, Level 9						
<b>14.00 - 15.00</b>	<b>Session M: Hepatitis prevention, treatment, and care in prisons</b> Room: Montreal A & B, Level 11 Chairs: Andrew Lloyd and Lisa Barrett	<b>14.00 - 15.00</b>	<b>Session N: Enhancing hepatitis C treatment</b> Room: Montreal C & D, Level 11 Chairs: Brian Conway and Anne Øvrehus	<b>14.00 - 15.00</b>	<b>Session O: Models of care: targeted interventions in various settings</b> Room: Fortifications, Level 9 Chairs: Alexandra King and Shashi Kapadia	<b>14.00 - 15.00</b>	<b>Session: Peer-based models of care: Learning from our communities</b> Room: Ville-Marie, Level 9 Chairs: Jude Byrne and Matthew Bonn
<b>14.00 - 14.15</b>	<b>The hepatitis C virus (HCV) cascade of care in the New York City (NYC) jail system</b> Justin Chan, Correctional Health Services, NYC Health + Hospitals, United States	<b>14.00 - 14.15</b>	<b>Nurse-led, community-based hepatitis C treatment is feasible and effective among people who inject drugs and their injecting network: the HCV treatment and prevention (TAP) study</b> Joseph Doyle, Burnet Institute, Australia	<b>14.00 - 14.15</b>	<b>Approaches to providing hepatitis C viremia testing to people who inject drugs in Georgia, Head Start (Hepatitis Elimination Through Access to Diagnostics) Georgia</b> Mara Japardze, FIRD, Switzerland	<b>14.00 - 14.15</b>	<b>Peer-led approach on treatment of Hepatitis C</b> Manasseh Muriithi, MDM-france, Kenya
<b>14.15 - 14.30</b>	<b>Injecting culture following prison-wide hepatitis C treatment scale-up: negotiating risk after cure</b> Lisa Lafferty, UNSW Sydney, Australia	<b>14.15 - 14.30</b>	<b>Comparing trial designs for HCV treatment as prevention: An empirical evaluation</b> Natasha Martin, University Of California San Diego, United States	<b>14.15 - 14.30</b>	<b>Increasing access to addiction services for Indigenous communities in Quebec: An integrated model of care between Onen'to:kon Healing Lodge, Stephanie Marsan, Centre hospitalier de l'Université De Montréal, Canada</b>	<b>14.15 - 14.30</b>	<b>A peer-based support-model for HCV treatment for PWID, integrated into a public healthcare facility in Hanoi, Vietnam</b> Mathilde Laval, Medecins Du Monde, France
<b>14.30 - 14.45</b>	<b>Injecting culture following prison-wide hepatitis C treatment scale-up: negotiating risk after cure</b> Sonia Schroeder, Burnet Institute, Australia	<b>14.30 - 14.45</b>	<b>Promise and pharmaceuticalisation in the era of direct-acting antivirals</b> Jake Rance, Centre For Social Research In Health, Australia	<b>14.30 - 14.45</b>	<b>Micro-elimination of Hepatitis C among people who use drugs in an Indigenous community in Saskatchewan Canada</b> Noreen Reed, Ahiakkoop Health Clinic, Canada	<b>14.30 - 14.45</b>	<b>The Hepatitis Bus – A Norwegian drug user initiative</b> Ronny Bjernestad, proLAR Nett, Norway
<b>14.45 - 14.50</b>	<b>Perceived barriers to and facilitators of HCV treatment uptake in jail and linkage to HCV care after incarceration: a qualitative study</b> Matthew Akiyama, Montefiore Medical Center, United States	<b>14.45 - 14.50</b>	<b>Real-world outcomes in Patients with Chronic Hepatitis C Virus Infection with Opioid Substitution Therapy, Mental Disorders, or Alcohol use Disorder Treated with Glecaprevir/Pibrentasvir: Data From The German Hepatitis C-Registry</b> Stefan Christensen, CIM Münster, Germany	<b>14.45 - 14.50</b>	<b>Successful treatment of hepatitis C among people who inject drugs in Nairobi, Kenya</b> Gladys Nowei, Medecins Du Monde, Kenya	<b>14.45 - 14.50</b>	<b>Community-based organization spearheads efforts to translate HCV interventions to prison settings in Jakarta</b> Caroline Thomas, Koalisi Satu Hati, Indonesia
<b>14.50 - 14.55</b>	<b>Enhancing linkage to hepatitis C care upon release from Canadian provincial prisons: the population-level impact on hepatitis C transmission among people who inject drugs in Montréal</b> Arnaud Godin, McGill University, Canada	<b>14.50 - 14.55</b>	<b>Real-world outcomes from people who use drugs with chronic hepatitis C virus infection treated with glecaprevir/pibrentasvir: A pooled analysis of post-marketing observational studies</b> Juliette Foucher, Hôpital de Haut Leveque, France	<b>14.50 - 14.55</b>	<b>Pharmacist-led HCV screening, diagnosis and treatment in an opioid substitution therapy outpatient pharmacy</b> Colter Young, Shoppers Drug Mart, Canada	<b>14.50 - 14.55</b>	<b>Can patient groups lead diagnosis and treatment in prisons of resource limited settings? We are doing it!</b> Jean-Luc El Kaim, Coalition Plus, France
<b>14.55 - 15.00</b>	<b>Disparities in Hepatitis C virus (HCV) care across Quebec's provincial prisons: Implications for HCV micro-elimination</b> Nadine Kronfli, McGill University, Canada	<b>14.55 - 15.00</b>	<b>Actively injecting PWID who use stimulants can be successfully treated for HCV infection</b> Sigurdur Olafsson, Landspítali University Hospital, Iceland	<b>14.55 - 15.00</b>	<b>Evaluation of the Xpert HCV Viral Load Fingerstick assay in the harm reduction setting in Catalonia, Spain</b> Verónica Saludes, Germans Trias I Pujol University Hospital Research Institute (Iqtp), Spain	<b>14.55 - 15.00</b>	<b>Methadone maintenance treatment program (MMTP) in Nepal: Role of user-led organizations in engaging and empowering MMTP patients</b> Ranjit Tiwari, National User Network of Nepal, Nepal
<b>15.00 - 15.45</b>	<b>Coffee Break and Poster Tour</b> Level 8						
<b>15.10 - 15.40</b>	<b>Poster Tour 3: Clinical</b>			<b>Poster Tour 4: Models of Care</b> Chair: John Dillon			
<b>15.10 - 15.15</b>	<b>Morbidity And Mortality In HCV-Infected People Who Use Drugs (PWUD): Beyond the SVR12</b> Tianna Magel, Vancouver Infectious Diseases Centre, Canada						
<b>15.15 - 15.20</b>	<b>Effect of a Single-Day Investigation for HCV Infection on Treatment Initiation among PWID, Before and After Universal Access to Direct Acting Antivirals</b> Valérie Martel-Laferrière, CHUM, Canada						
<b>15.20 - 15.25</b>	<b>Working Towards Micro-Elimination of HCV in PWID. A Direct Observed Therapy vs Fortnightly Collection Study for HCV Treatment – Advance HCV Study</b> Christian Sharkey, NHS Tayside, United Kingdom						
<b>15.25 - 15.30</b>	<b>Randomized Clinical Trial to Test E-health Interventions to Improve Adherence to a Once-daily Single-tablet Regimen in Patients with Chronic Hepatitis C Virus Infection</b> Jeffrey Weiss, Mount Sinai, United States						
<b>15.30 - 15.35</b>	<b>Feasibility of rapid hepatitis C point-of-care RNA testing and treatment at an integrated supervised consumption site in Toronto, Canada</b> Kate Mason, Toronto Community Hep C Program, Canada						
<b>15.35 - 15.40</b>	<b>Micro Elimination Enhanced by a Network Connecting all Detoxification and Substitution Programs with an Expertized Hepatology Clinic in Northern Greece</b> Efrosyni Tsirogianni, Greek Organisation Against Drugs, Greece						
<b>15.45 - 17.15</b>	<b>Session P: Prisons</b> Room: Montreal A & B, Level 11 Chairs: Nadine Kronfli and Matthew Akiyama		<b>Session Q: Strategies to enhance testing and diagnosis</b> Room: Montreal C & D, Level 11 Chairs: Jason Grebely and Karina Lacombe		<b>Session R: Neglected but not forgotten: innovative ways to engage women who use drugs into HCV care (supported by IAS)</b> Room: Fortifications, Level 9 Chairs: Marina Klein and Judy Chang		
<b>15.45 - 16.05</b>	<b>Tackling prisoner health via an upstream public health approach</b> Prem Thurairajah, Changi General Hospital, Singapore	<b>15.45 - 16.05</b>	<b>Diagnostics for hepatitis C: Where do we stand and what lies ahead?</b> Sonjelle Shilton, The Foundation for Innovative New Diagnostics, Switzerland	<b>15.45 - 15.50</b>	<b>Myanmar Video</b> Médecins du Monde		
<b>16.05 - 16.25</b>	<b>Project ECHO as a model for hepatitis care in the prisons</b> Karla Thornton, University of New Mexico, United States						
<b>16.25 - 16.45</b>	<b>Hepatitis C testing and treatment in correctional centers in the United States</b> Anne Spaulding, Emory University, United States						
<b>16.45 - 17.15</b>	<b>Questions &amp; Discussion</b>		<b>Questions &amp; Discussion</b>		<b>Questions &amp; Discussion</b>		
<b>19:00 - 23:00</b>	<b>Conference Dinner</b>						

<b>Day 3</b>				
<b>Moving beyond hepatitis C</b>				
<b>09.00 Registration</b>				
<b>09.00 - 09.30 Light Breakfast and Poster Viewing</b>				
<b>Level 8</b>				
09.30 - 11.00 <b>Session S: Hepatitis C and Health for People who Use Drugs</b> Room: Montreal Ballroom, Level 11 Chairs: Naveed Janjua and Laurence Marsillan				
09.30 - 09.50 <b>Beyond Hepatitis C: Improving the health and lives of people who use drugs</b> Mark Tyndall, University of British Columbia, Canada				
09.50 - 10.10 <b>Health economics of substance use and hepatitis C: Informing practice and policy</b> Bruce Schackman, Weill Cornell Medical College, United States				
10.10 - 10.30 <b>Questions &amp; Discussion</b>				
10.30 - 10.45 <b>Comparing adherence to once-daily and twice daily DAA therapy among people with recent injection drug use or current opioid substitution therapy: The SIMPLIFY and D3FEAT studies</b> Evan Cunningham, The Kirby Institute, UNSW Sydney, Australia				
10.45 - 11.00 <b>Clinical effectiveness of pharmacy-led versus conventionally delivered antiviral treatment for hepatitis C in patients receiving opioid substitution therapy: A pragmatic cluster randomised trial</b> Andrew Radley, NHS Tayside, United Kingdom				
<b>11.00 - 11.30 Coffee Break and Poster Viewing</b>				
<b>Level 8</b>				
11.30 - 12.00 <b>Session T: 'Connecting with Care' – A Film Preview of Models of Care from Canada and beyond'</b> Room: Montreal Ballroom, Level 11 Chairs: Conor Ashleigh				
11.30 - 11.35 <b>Introduction</b> Conor Ashleigh, Visual Story Teller, Australia				
11.35 - 11.40 <b>The ENHANCE project, an intervention to increase hepatitis C diagnosis and treatment in Tehran, Iran</b> Maryam Ajavi, ENHANCE, Australia				
11.40 - 11.45 <b>Montreal's many models of care</b> Julie Bruneau, CRISM, Canada; Huo Bissonnet, Centre Sida Amitie, Canada; Martin Page, Dopamine, Canada				
11.45 - 11.50 <b>A Saskatchewan Story, Athahkakoop's Indigenous Model of Care</b> Noreen Reed, Athahkakoop Clinic, Canada; Jennifer Ahenakew, Athahkakoop, Canada; Stuart Skinner, University Of Saskatchewan, Canada				
11.50 - 12.00 <b>Questions &amp; Discussion</b>				
<b>12.00 - 13.45 Lunch &amp; Poster Viewing</b>				
<b>Level 8</b>				
<b>12.30 - 13.30 INHSU GAM</b>				
<b>Room: Fortifications, Level 9</b>				
13.45 - 14.45 <b>Session U: Hepatitis C reinfection</b> Room: Montreal A & B, Level 11 Chairs: Charlotte Laniece and Phillip Read	13.45 - 14.45 <b>Session V: Beyond hepatitis C</b> Room: Montreal C & D, Level 11 Chairs: Stone Crawford and Sarah Larney	13.45 - 14.45 <b>Session W: Models of care to enhance engagement in care</b> Room: Fortifications, Level 9 Chairs: Lynn Taylor and Chris Fraser		
13.45 - 14.00 <b>Hepatitis C Virus Reinfection after Successful Treatment with Direct-Acting Antiviral Therapy in Canada</b> Naveed Janjua, BC Centre For Disease Control, Canada	13.45 - 14.00 <b>Operationalizing the risk environment: spatial distribution of people who inject drugs and hotspots of social injecting activity in Montreal, Canada</b> Nanor Minoyan, University of Montreal CRCHUM, Canada	13.45 - 14.00 <b>Community centric HCV testing and treatment for PWID in Manipur, India - The Head Start Project</b> Babu Entroor Ramachandran, FIND, India		
14.00 - 14.15 <b>Risk of HCV reinfection and associated patterns of behaviour among men who inject drugs or who have sex with men in Canada</b> Brendan Jacka, Research Institute, Centre hospitalier de l'Université de Montréal (CHUM), Canada	14.00 - 14.15 <b>The impact of opioid agonist treatment on mortality among people who inject drugs: A 3 site modelling analysis</b> Jack Stone, University Of Bristol, United Kingdom	14.00 - 14.15 <b>'Get Tested LeEDs': (Re)-diagnosing and (re)-engaging PWID with blood borne viruses (BBV) in an urban emergency department</b> Emma Page, Leeds Teaching Hospitals Trust, United Kingdom		
14.15 - 14.30 <b>Hepatitis C virus reinfection following antiviral treatment among people who use or inject drugs: a systematic review and meta-analysis</b> Behzad Hajari, The Kirby Institute, UNSW Sydney, Australia	14.15 - 14.30 <b>Growing old with drugs. Preliminary results from a qualitative study on the aging process of drug users in opioid substitution treatment</b> Margheria Luciani, University Of Applied Sciences Of Southern Switzerland, Switzerland	14.15 - 14.30 <b>Treating people where they are: Nurse-led hepatitis C (HCV) micro-elimination project for networks of people with recent injecting drug use in Victoria, Canada</b> Karen Lundgren, Cool Aid Community Health Centre, Canada		
14.30 - 14.35 <b>Drug use and reinfection during and following HCV treatment with elbasvir/grazoprevir (EBV/GZR) among patients receiving opioid agonist therapy: Final results from the CO-STAR study</b> Gregory Dore, The Kirby Institute, UNSW Sydney, Australia	14.30 - 14.35 <b>Impacts of Hepatitis C Virus Infection Treatment for Patients in Treatment for Opioid Use Disorder</b> Robert Heimer, Yale University School of Public Health, United States	14.30 - 14.35 <b>A cost-benefit analysis of primary versus hospital-based specialist care for direct acting antiviral hepatitis C treatment</b> Nick Scott, Burnet Institute, Australia		
14.35 - 14.40 <b>Low rate of reinfection among a cohort of people who inject drugs successfully treated for hepatitis C virus infection within a multidisciplinary program</b> Brian Conway, Vancouver Infectious Disease Centre, Canada	14.35 - 14.40 <b>An international systematic review of methadone and buprenorphine doses used in the treatment of opioid use disorder</b> Sarah Larney, National Drug And Alcohol Research Centre, UNSW Sydney, Australia	14.35 - 14.40 <b>Engaging mother-infant dyads in hepatitis C care through perinatal pediatric infectious diseases consultation</b> Rachel Epstein, Boston Medical Center, United States		
14.40 - 14.45 <b>Rare HCV Re-Infection after DAA Treatment in an Integrated All-Under-One-Roof Care Setting</b> Claudia Bernardini, ARUD, Switzerland	14.40 - 14.45 <b>High Rates of Opioid Overdose and Witnessed Overdose in PWID Receiving HCV Treatment: Data from the ANCHOR Study</b> Elana Rosenthal, University Of Maryland School Of Medicine, United States	14.40 - 14.45 <b>Removing health insurance barriers and incorporating harm reduction with a physician - nurse - pharmacist team, to optimize hepatitis c virus (HCV) treatment in a U.S. co-located HCV/methadone maintenance program</b> Jackie Habchi, Codac Behavioral Health, United States		
<b>14.45 - 15.15 Coffee Break and Poster Viewing</b>				
15.15 - 16.30 <b>Session X: Beyond Injecting Drug Use</b> Room: Montreal A & B, Level 11 Chairs: Suzanne Brissette and Philip Bruggmann	15.15 - 16.30 <b>Session Y: How do we move forward policies on hepatitis C and drug use?</b> Room: Montreal C & D, Level 11 Chairs: Jeffrey Lazarus and Annette Gaudino	15.15 - 16.30 <b>Session Z: The critical role of the nurse for integrating health care for people who use drugs</b> Room: Fortifications, Level 9 Chairs: Lesley Gallagher and Donna Zukowski		
15.15 - 15.35 <b>Emerging trends in stimulant use and the impact on hepatitis C</b> Francisco Inacio Bastos, Oswaldo Cruz Foundation, Brazil	15.15 - 15.35 <b>Policies to enhance access to hepatitis C prevention and treatment for people who use drugs</b> Niklas Luhmann, World Health Organisation, Switzerland	15.15 - 15.25 <b>Easy Access Within the Clinic and Corrections</b> Janet Catt, Kings College Hospital NHS Foundation Trust, United Kingdom		
15.35 - 15.55 <b>Emerging Trends in alcohol and the impact on hepatitis C</b> Jurgen Rehm, Centre for Addiction and Mental Health, Canada	15.35 - 15.55 <b>Taking stock of a decade of drug policy: Where have we come and where to next?</b> Marie Nougier, International Drug Policy Consortium, Country	15.25 - 15.35 <b>Collaborating Within the Addiction Clinic</b> Sidsel Sejr, KABS, Glostrup Kommune, Denmark		
15.55 - 16.15 <b>Emerging Trends in mental health and the impact on hepatitis C</b> Didier Jutras-Aswad, Canadian Research Initiative in Substance Misuse (CRISM), Canada	15.55 - 16.15 <b>Market dynamics and the hepatitis C response: Facilitating policy decisions to improve affordable, equitable access to treatment</b> Sean Regan, Clinton Health Access Initiative, United States	15.35 - 15.45 <b>Treat and Teach - Outreach to Indigenous Communities</b> Lesley Gallagher, Saskatchewan Infectious Disease Care Network (SIDCN), Canada		
16.15 - 16.30 <b>Questions &amp; Discussion</b>	16.15 - 16.30 <b>Questions &amp; Discussion</b>	15.45 - 15.55 <b>The Independent Nurse Working as a Physician Delegate</b> Jan Tait, Ninewells Hospital Dundee, United Kingdom		
16.30 - 16.40 <b>Room Movement</b>		15.55 - 16.05 <b>Managing HCV Elimination</b> Heidi Friðriksdóttir, Landspítali University Hospital, Iceland		
16.40 - 17.30 <b>Conference Closing</b> Room: Montreal Ballroom, Level 11 Chairs: Julie Bruneau and Marina Klein		16.05 - 16.15 <b>Confidence to treat HCV through Mentorship</b> Manasseh Murage, Médecins du Monde, Kenya		
16.40 - 16.50 <b>Community Rapporteur</b>		16.15 - 16.30 <b>Questions &amp; Discussion</b>		
16.50 - 17.00 <b>Policy &amp; Epidemiology Rapporteur</b> Jack Stone, University of Bristol, United Kingdom				
17.00 - 17.10 <b>Linkage to Care &amp; Treatment Rapporteur</b> Tracy Swan, Consultant United States				
17.10 - 17.20 <b>Models of Care Rapporteur</b> John Dillon, University of Dundee, Scotland				
17.20 - 17.30 <b>Conference Closing and Introduction of Upcoming Conference</b>				